Childhood Acute Lymphoblastic Leukemia

33

Pipeline Programs↗

1

Active Trials↗

15

Companies Involved↗

Childhood Acute Lymphoblastic Leukemia is a moderately active landscape with 33 programs across 15 companies. The most active players are Nanjing Chia-tai Tianqing Pharmaceutical, EMD Serono, Eli Lilly. 6 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

53/100

Pipeline Velocity

0/100

Mech. Concentration

20/100

Completion Rate

71/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Nanjing Chia-tai Tianqing Pharmaceutical

1 program

EMD Serono

1 program

Eli Lilly

1 program

Genzyme, a Sanofi Company

1 program

Princess Maxima Center for Pediatric Oncology

1 program

Viatris Specialty LLC

1 program

Pipeline

Programs by Phase

Analysis

Modality Breakdown

86%

Small molecule

32 of 37 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 37 classified programs, each share of the total. Modality classified for 100% of 38 pipeline programs.

Analysis

Trial Status

11

clinical trials

Completed5 · 45%

Unknown status3 · 27%

Terminated2 · 18%

Recruiting1 · 9%

Clinical Trials

Trial Activity

11 trials

Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia

Recruiting·—·Phase 2·NCT05827549·90 enrolled

ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia (ALL) - 6MP Consolidation Therapy

Completed·—·Phase 3·NCT00816049·775 enrolled

ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia Intermittent Versus Continuous PEG Asparaginase

Completed·—·Phase 3·NCT00819351·650 enrolled

Therapeutic Interventions For Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL)

Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT01506453·51 enrolled

Safety of Clofarabine With Multiagent Chemotherapy in Childhood Acute Lymphoblastic Leukemia

Completed·UUniversity Hospital, Lille·Phase 1·NCT01279096·20 enrolled

Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT01324180·14 enrolled

Treatment of Childhood Acute Lymphoblastic Leukemia

Terminated·—·Phase 3·NCT00165087·491 enrolled

CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL)

Terminated·UUniversity College, London·Phase 1/2·NCT01195480·29 enrolled

The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia

Unknown status·SSun Yat-sen University·Phase 4·NCT00846703·600 enrolled

Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)

Unknown status·FFederal Research Institute of Pediatric Hematology, Oncology and Immunology·N/A·NCT03390387·4,000 enrolled

Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2008

Unknown status·FFederal Research Institute of Pediatric Hematology, Oncology and Immunology·N/A·NCT01953770·3,000 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)